ENDOMETRIAL SEROUS ADENOCARCINOMA
Clinical trials for ENDOMETRIAL SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without their cancer getting worse. About 813 participants with stage III, IV, or recu…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:21 UTC
-
New hope for advanced endometrial cancer: three drug combos face off
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced or recurrent endometrial cancer. The goal was to see which combination worked best to stop the cancer from growing. Participants received either paclitaxel/carboplatin/bevacizumab, paclitaxel/carbopla…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:21 UTC
-
New drug cocktails aim to halt return of uterine cancer
Disease control OngoingThis study tests several drug combinations in 288 women whose endometrial cancer has returned or not responded to treatment. The drugs work by blocking enzymes that help cancer grow or by boosting the immune system to attack tumors. The goal is to see if these combinations can sl…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New drug duo targets Hard-to-Treat brain tumors
Disease control OngoingThis early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New scan method may spare women unnecessary surgery for uterine cancer
Knowledge-focused OngoingThis study looks at whether a PET/CT scan and a special dye (indocyanine green) can better detect cancer that has spread to lymph nodes in women with high-risk endometrial cancer. About 100 women with aggressive uterine cancers will get these tests before surgery. The goal is to …
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 09:03 UTC
-
Can a short drug course slow uterine cancer growth before surgery?
Knowledge-focused OngoingThis early-phase trial gives a drug called triapine to 12 people with a rare uterine cancer (serous adenocarcinoma) just before their scheduled hysterectomy. The goal is to see if the drug changes certain markers in the tumor tissue, which may indicate it slows cancer growth. Par…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 26, 2026 09:01 UTC